Quanterix Corporation Announces Date of 2026 Annual Meeting

Key Terms

Rule 14a-8 regulatory

Rule 14a-8 is a U.S. Securities and Exchange Commission regulation that lets eligible shareholders put proposals on a public company’s proxy ballot for an annual meeting, provided they meet basic ownership and filing requirements. It matters to investors because it creates a formal way to raise governance or strategic issues and force a company-wide vote—like getting an item onto the agenda of a neighborhood association meeting once you’ve lived there long enough—so shareholders can push for change or influence management decisions.

proxy statement regulatory

A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.

View in glossary

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection (the “Company”), today announced that the Company’s 2026 annual meeting of shareholders (the “Annual Meeting”) will be held virtually, by means of remote communication, on Tuesday, June 9, 2026 at 10:00 am Eastern Time. Stockholders of record of the Company’s common stock as of the close of business on April 14, 2026 will be entitled to vote at the Annual Meeting. Additional information regarding the Annual Meeting will be provided in the Company’s proxy statement.

Because the date of the Annual Meeting has been advanced by more than thirty (30) days from the anniversary date of the Company’s 2025 annual meeting, the Company has set a new deadline for the receipt of shareholder proposals submitted pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for inclusion in the Company’s proxy materials for the Annual Meeting. In order to be considered timely, such proposals must be received by the Company’s Secretary no later than April 6, 2026. Any proposal submitted after the above deadline will not be considered timely and will be excluded from the Company’s proxy materials.

Additionally, in accordance with the advance notice provisions set forth in the Company’s Bylaws, in order for a shareholder proposal to be submitted outside of Rule 14a-8 of the Exchange Act or a director nomination submitted by a shareholder to be considered timely, it must be received by the Company’s Secretary not later than April 6, 2026.

About Quanterix

Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa^® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,300 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company^®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,439 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue -- advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260327100682/en/

Investor Relations Contact:
Joshua Young
(508) 846-3327
ir@quanterix.com

Source: Quanterix Corporation